Key facts
- iView Therapeutics’s last known valuation is $107.4M (Jun 2025).
- It has raised $39.2M across 2 recorded rounds; the latest was Early Stage VC ($9.2M) in May 2024.
- Notable investors include Cowin Capital, Proxima Ventures (China), BioAdvance Capital (Conshohocken), Alpha Bioventure, Chongqing Dian Petrochemical Medical Fund Management — 16 tracked in total.
- iView Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently Jun 2025 ($9.2M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for iView Therapeutics
Funding rounds
2 roundsAbout iView Therapeutics
Developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology. The company develops drugs including long-acting povidone-iodine ophthalmic formulations for the treatment of active infections of the conjunctiva and cornea, enabling the medical community to combat anti-viral and antimicrobial conditions effectively.
- Sector
- Healthcare
- HQ
- Cranbury, NJ, United States
- Founded
- 2015
- Employees
- 11
- Website
- iviewtherapeutics.com/
- Ownership
- Privately Held (backing)
iView Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iView Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iView Therapeutics in its N-PORT filings yet. We sweep new filings monthly.